

January 23, 2024

Press Release

Mitsubishi Tanabe Pharma Corporation
Pfizer Japan Inc.
The Research Foundation for Microbial Diseases of Osaka University

<p style="text-align: center;">Co-promotion of “GOBIK Aqueous Suspension Syringes”, Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine</p>

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereafter, "MTPC") and Pfizer Japan Inc. (Head Office: Shibuya-ku, Tokyo; President: Akihisa Harada, hereafter "Pfizer") will conduct co-promotion activities in Japan for "GOBIK Aqueous Suspension Injection Syringes" (hereafter "GOBIK"), Adsorbed Diphtheria-Purified Pertussis-Tetanus-Inactivated Polio-Haemophilus type b conjugate Combined Vaccine, for which the Research Foundation for Microbial Diseases of Osaka University (Headquarters: Suita-city, Osaka; Director General: Yoshihiro Yoneda; hereafter, "BIKEN") has been obtained the marketing approval. GOBIK will be manufactured by BIKEN, distributed by MTPC and jointly promoted by MTPC and Pfizer.

GOBIK is a vaccine that combined the antigenic components of TETRABIK (adsorbed diphtheria-purified pertussis-tetanus-inactivated polio [Sabin strain] combined vaccine) with those of Haemophilus influenzae type b (Hib). GOBIK is a vaccine jointly developed by BIKEN and MTPC, and was first approved in Japan as the combination vaccine for five diseases on March 27, 2023. The combination vaccine for five diseases has been selected as one of the vaccines with high development priority according to the "Basic plan about vaccination" stipulated in 2014. At present, the total number of shots of routine vaccinations required by two years old is twenty or more, and combination vaccines will reduce the number of shots and the burden on infants and guardians.

Routine vaccinations with the combination vaccine for five diseases is planned to begin in April 2024, and preparations are underway for the launch of GOBIK in March 2024. MTPC, Pfizer and BIKEN will continue to contribute to public health in Japan through the manufacture, stable supply and promotion of GOBIK.

◆ **Contact information**

Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group,
Corporate Communications Div., Osaka Corporate Communications Dept.)

TEL: 06-6205-5119

Public Relations Section, The Research Foundation for Microbial Diseases of
Osaka University

TEL: 06-6877-4802

◆ Please refer to the following URL for the infections to be prevented with pertussis, diphtheria, tetanus, inactivated polio and Hib combined vaccine.

<https://www.cdc.gov/vaccines/parents/diseases/index.html>

◆ **About Mitsubishi Tanabe Pharma Corporation**

Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Dosho-machi, Osaka, the birthplace of Japan's pharmaceutical industry. MCG has positioned health care as its strategic focus in its management policy, "Forging the future". MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to <https://www.mt-pharma.co.jp/e/>

◆ **About Pfizer**

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health



Mitsubishi Tanabe Pharma



BIKEN

THE RESEARCH FOUNDATION FOR
MICROBIAL DISEASES OF OSAKA UNIVERSITY

care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, Pfizer has worked to make a difference for all who rely on us. For more information, go to www.pfizer.com (Pfizer Inc.), www.pfizer.co.jp, [Instagram](#), [X](#) (Pfizer Japan Inc.)

◆ **About Research Foundation for Microbial Diseases of Osaka University**

The BIKEN is a Specialty Bio-Pharmaceutical Organization engaged in the Research, Development and Supply of Vaccines. Since its establishment in 1934, BIKEN has contributed to public health by developing, manufacturing and supplying a number of first vaccines made in Japan and providing advanced laboratory test services. Based on its mission "Protect the precious lives of people around the world through excellent vaccines." the BIKEN will continue to pursue the advancement of advanced science and unique biotechnology toward a healthy society free from disease anxiety. <https://www.biken.or.jp/english>